Critically, this also means that once drug efficacy has been demonstrated, a new study claiming to show lack of efficacy with a different protocol merely demonstrates that the protocol was not well-designed.

A drug company could easily generate a trial in which their competitor's product was not effective - but it wouldn't mean very much. The same is true for a trial employing a protocol that wouldn't be accepted by experts with a clear interest…